Mesenchymal stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage.
Mesenchymal stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage.
复制标题
DOI：
10.2174/157488806775269151
复制
发表时间：
2006-01-01
影响因子：
2.7
通讯作者：
Mehlhorn, Alexander
中科院分区：
文献类型：
--
作者：
Niemeyer, Philipp;Krause, Ulf;Mehlhorn, Alexander
间充质干细胞（MSC）可以从人骨髓抽吸中获得，由于其分化潜力和良好的体外培养特性，是间充质组织再生的一个有吸引力的细胞系。无论是在体外还是在体内，它们都能分化成软骨细胞、骨骼细胞、肌腱细胞和脂肪细胞，而且与胚胎干细胞不同的是，它们不受伦理审查。根据组织工程的概念，在三维支架上培养，它们已经成功地用于重建间充质组织，在许多涉及小型和大型动物模型的研究中。近年来，几个研究小组对MSC的免疫学特性进行了研究。在现有文献的基础上，MSC必须被称为免疫特权，它们似乎可用于hla非依赖性细胞移植。虽然临床间充质干细胞移植在人类的初步研究中也取得了成功，但仍有许多问题有待澄清，强调在考虑大规模临床应用之前需要进一步深入研究。只有这样，才能证明相关的高期望是否合理。
Mesenchymal stem cells (MSC) can be obtained from human bone marrow aspirates and, thanks to their differentiation potential and excellent in vitro culture properties, represent an attractive cell line for the regeneration of mesenchymal tissue. Both in vitro and in vivo, they can differentiate into cartilage, bone, tendons and fat cells, and-in contrast to embryonic stem cells-they are not under ethical scrutiny. Cultured on three-dimensional scaffolds according to the tissue engineering concept, they have already been successfully employed for reconstruction of mesenchymal tissues in numerous studies involving both small and large animal models. Recently, immunological properties of MSC have been investigated by several groups. On the basis of the available literature, MSC have to be referred to as immune privileged, and they seem to be available for HLA-independent cell transplantation. While clinical MSC transplantation has also been successfully performed in pilot studies in humans, numerous points still remain to be clarified, underscoring the need for further intensive research before large-scale clinical application can be contemplated. Only then can it be shown whether the associated high expectations are justified.